Extrawell Pharmaceutical Holdings Ltd (0858) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Extrawell Pharmaceutical Holdings Ltd stock HK$0.05, price HK$0.06, that is 12.2% below the price, quality 47 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Extrawell Pharmaceutical Holdings Ltd
0858 · HKExpensive (fair value 12% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range HK$0.0260 – HK$0.1760 · fair‑value band HK$0.0464 – HK$0.0607 · the HK$0.0610 price screens above the HK$0.0535 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 16, 2026.
Every Wednesday you see whether Extrawell Pharmaceutical Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sell of pharmaceutical products in the People's Republic of China and Hong Kong.
Show moreShow less
The company manufactures transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing; and ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels.
It is also involved in marketing and distribution of imported pharmaceutical products, including Skin-Cap for the treatment of itching, irritation, redness, and scaly skin issues; and Millibar for the treatment of high blood pressure.
In addition, the company develops oral insulin product, which is in clinical trial stage for the treatment of diabetes. Further, the company engages in the provision of agency services and property investment business.
Extrawell Pharmaceutical Holdings Limited was incorporated in 1998 and is headquartered in Quarry Bay, Hong Kong.
Stock analysis
Extrawell Pharmaceutical Holdings Ltd (0858) currently trades at HK$0.0610, while our estimate is HK$0.0535, 12% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: HK$0.0464 (bear) to HK$0.0607 (bull), the price of HK$0.0610 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2018: revenue and profit before it include the divested business. Growth is measured afresh from 2018.
Extrawell Pharmaceutical Holdings Ltd reported revenue of HK$51.5M in FY2026 versus HK$73.9M in FY2022, a compound −8.6%/yr. Reported net income was −HK$980M in FY2026.
Key figures
Market cap HK$156M (≈ $19.8M) Micro · P/S ratio 2.65 · Return on equity −114% · Return on assets (EBIT) −1.0% (5-year average) · Operating margin −24.9% · Revenue (TTM) HK$51.5M · Revenue growth (YoY) −9.0% · EPS growth (YoY) +12.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −12%, 0858 screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
0858 screens overvalued: fair value 12% below the price. Compare with Merck KGaA →
Compare Extrawell Pharmaceutical Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Dividend yield by industry
- EV/EBITDA by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $85.57 | $113.53 | +33% | vs 0858 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥46.88 | ¥52.43 | +12% | vs 0858 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,900 | ₹1,983 | +4% | vs 0858 |
| Haleon plc HLN | $9.08 | $8.47 | −7% | vs 0858 |
| Merck KGaA MRK | €148.40 | €108.83 | −27% | vs 0858 |
| Galderma Group GALD | CHF 184.70 | CHF 112.46 | −39% | vs 0858 |
| Takeda Pharmaceutical Company TAK | $21.27 | $11.23 | −47% | vs 0858 |
| Sandoz Group SDZ | CHF 81.24 | CHF 41.06 | −49% | vs 0858 |
| Teva Pharmaceutical Industries Limited TEVA | $42.23 | $20.74 | −51% | vs 0858 |
| Divi's Laboratories Limited DIVISLAB | ₹11,178 | ₹1,567 | −86% | vs 0858 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Extrawell Pharmaceutical Holdings Ltd (0858) overvalued or undervalued?
What is the fair value of 0858?
What is the quality score of 0858?
What is the price target for Extrawell Pharmaceutical Holdings Ltd (0858)?
What is the Extrawell Pharmaceutical Holdings Ltd stock forecast for 2026?
What is the revenue of Extrawell Pharmaceutical Holdings Ltd (0858)?
What is the intrinsic value of Extrawell Pharmaceutical Holdings Ltd (0858)?
Is Extrawell Pharmaceutical Holdings Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 0858?
How much is Extrawell Pharmaceutical Holdings Ltd worth?
What do the bullish and bearish scenarios say about 0858?
How solid is the balance sheet of Extrawell Pharmaceutical Holdings Ltd (0858)?
How far is 0858 from its 52-week high?
Which stocks are comparable to Extrawell Pharmaceutical Holdings Ltd?
Is Extrawell Pharmaceutical Holdings Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Extrawell Pharmaceutical Holdings Ltd (0858)?
What should I pay attention to with Extrawell Pharmaceutical Holdings Ltd right now?
Key figures of Extrawell Pharmaceutical Holdings Ltd
How large is the market capitalisation of Extrawell Pharmaceutical Holdings Ltd (0858)?
What is the P/S ratio of Extrawell Pharmaceutical Holdings Ltd (0858)?
What is the return on equity of Extrawell Pharmaceutical Holdings Ltd (0858)?
What is the EBIT return on assets of Extrawell Pharmaceutical Holdings Ltd (0858)?
What is the operating margin of Extrawell Pharmaceutical Holdings Ltd (0858)?
How fast is revenue growing at Extrawell Pharmaceutical Holdings Ltd (0858)?
How fast are earnings growing at Extrawell Pharmaceutical Holdings Ltd (0858)?
How much free cash flow does Extrawell Pharmaceutical Holdings Ltd (0858) generate?
How much net debt does Extrawell Pharmaceutical Holdings Ltd (0858) carry?
Watch Extrawell Pharmaceutical Holdings Ltd in the live analysis
One click puts Extrawell Pharmaceutical Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.